Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- R&D NEWS IN BRIEF
June 1, 2009
- Otsuka HD: Sales of Healthcare Products Up to ¥676.7 Bil.
June 1, 2009
- GENERICS NEWS IN BRIEF
June 1, 2009
- Zeria: Mid-Term Sales Target Down to ¥73 Bil.
June 1, 2009
- Quintiles Named Most Favored CRO in 2 Independent Surveys
June 1, 2009
- ASKA: Profits Plummet with Flat Sales
June 1, 2009
- 60% of Patients Prefer In-House Prescriptions at Sanjou Hospital
June 1, 2009
- Seikagaku: Sales of Artz Up in Japan, China
June 1, 2009
- Cumulative Total of 787 Deaths Reported in Iressa-Treated Patients
June 1, 2009
- Nippon Chemiphar: Profits Sinks as Sales of Generics Increase
June 1, 2009
- Draft Report on Proper Preparation, Use of Fertilized Human Embryos Approved
June 1, 2009
- Rush of Orders on Gargles, Masks
June 1, 2009
- Wakamoto: Profits Down due to Poor Stock Management
June 1, 2009
- Champix Cuts Lifetime Medical Spending by ¥30,000
June 1, 2009
- Average Operating Profit Rate Down to 0.38% for Top-Four Wholesalers
June 1, 2009
- Teijin: Pharma & HHC Business Remains Bullish
June 1, 2009
- JSMI Announces Vision for Activation of OTC Drug Industry
June 1, 2009
- Suzuken: Sharp Fall in Profits Despite 3.4% Increase in Sales
June 1, 2009
- Meiji HD: Generics Bolster Pharma Business
June 1, 2009
- Reform of Profit Structure "Task of Pressing Urgency": Mr Kumakura
June 1, 2009
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…